title: Clinical features and treatment outcome of children with myeloid antigen coexpression in B-lineage acute lymphoblastic leukemia: a study of 151 Malaysian children.
abstract: The purpose of the study was to evaluate the incidence of myeloid antigen coexpression and its prognostic significance in childhood acute lymphoblastic leukemia (ALL) in Malaysia. A retrospective study was conducted of all ALL cases (< or = 12 years old) diagnosed and treated in University Hospital, Kuala Lumpur, Malaysia between 1 January 1992 and 30 May 1995, with available immunophenotype data. Presenting features and treatment outcome of 39 B-lineage ALL patients with myeloid antigen coexpression (My+B) were compared with 112 B-lineage ALL patients without myeloid antigen coexpression (My-B) for similarity in demographic, clinical and laboratory features and their treatment outcome. My+B and My-B patients were treated with a uniform treatment protocol. Myeloid antigen coexpression was defined as more than 30% isolated leukemic cells positive for CD13 and/or CD33. The ages at diagnoses ranged from 2 months to 12 years. Median age was 4 years. The incidence of myeloid antigen coexpression was 23 per cent. Univariate analyses showed that presenting features were similar between My+B and My-B with regard to age, sex, race, FAB morphology, white cell count, hemoglobin level, platelet count, liver/spleen size, central nervous system or mediastinal involvement, presence of lymphadenopathy, and proportion of blast cells detected in the marrow. Treatment outcome were not significant between the two groups. The 2-year event free survival was achieved in 44 per cent of My+B and 57 per cent of My-B (p = 0.11). The 2-year overall survival rates were 62 per cent for My+B vs. 77 per cent for My-B (p = 0.08). This study demonstrates that myeloid antigen coexpression is fairly common and constitutes 23 per cent of childhood ALL within the Malaysian population and that it is not an adverse risk factor in childhood ALL.
authors.affiliation: Department of Paediatrics, University Hospital, Kuala Lumpur, Malaysia. ngszemay@hotmail.com
authors.forename: S M
authors.initials: SM
authors.lastname: Ng
authors.forename: W A
authors.initials: WA
authors.lastname: Ariffin
authors.forename: H P
authors.initials: HP
authors.lastname: Lin
authors.forename: L L
authors.initials: LL
authors.lastname: Chan
authors.forename: Y M
authors.initials: YM
authors.lastname: Chin
mesh_terms: D017951:Antigen Presentation / Q000187:drug effects; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis* / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001402:B-Lymphocytes / Q000145:classification / Q000276:immunology; D015415:Biomarkers / Q000032:analysis; D002051:Burkitt Lymphoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D019070:Cell Lineage; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D015214:Antigens, Differentiation, Myelomonocytic; D015415:Biomarkers